Introduction {#section5-1757177416657162}
============

Short-term intravascular access devices, which include central venous and arterial catheters, are commonly used for the management of critically ill patients with the majority of patients receiving care that involves the use of these catheters ([@bibr6-1757177416657162]). The use of intravascular catheters is, however, associated with the risk of bloodstream infections (BSI); a leading cause of healthcare-associated infections (HCAI). In a recent survey reported by the Health Protection Agency (now Public Health England) blood stream infections accounted for 7.3% of all HCAI and of these 64% were in patients with a vascular access device ([@bibr9-1757177416657162]).

Infections associated with intravascular catheters are often categorised as either central-line associated bloodstream infection (CLABSI) or catheter-related bloodstream infection (CRBSI). The former term is often used in relation to epidemiological studies on the surveillance of bloodstream infections and the latter where a high degree of confidence in the origins of the infection is determined. The Centers for Disease Control and Prevention (CDC) recommends the CLABSI definition be used for surveillance of infections and defines it as: a confirmed BSI in any patient with a central venous catheter (CVC) present either at the time of or within a 48-h period before the detection of infection. CLABSI are likely therefore to overestimate the incidence of CRBSI, as they do not fully confirm the source of infection as the intravascular catheter. CRBSI is more frequently used in clinical research being a more precise and rigorous definition that requires isolation of the same microorganism from the catheter tip and peripheral blood or other validated methods including comparison of the numbers of microorganisms present in peripheral blood with samples obtained through the catheter or the differential time to positivity of blood obtained via the catheter versus peripheral blood ([@bibr3-1757177416657162]). For the purposes of this report we have used a single term and describe both CRBSI and CLABSI as CRBSI.

The risk of CRBSI is associated with a variety of factors including the site of insertion of the device and the severity of the patients underlying clinical condition. In 2009, the CDC estimated the number of CRBSI in intensive care units (ICUs) across the United States to be 18,000 ([@bibr26-1757177416657162]). In a pan-European survey of ICU patients, the incidence of CRBSI was in the range of 1--3.1 per 1000 patient days ([@bibr27-1757177416657162]). The reported incidence of CRBSI has decreased in more recently reported studies following various interventions including a care bundle approach. For example, in a national critical care programme in the UK, the incidence of CRBSI fell from 3.7 to 1.48 per 1000 patient days ([@bibr1-1757177416657162]). However, CRBSI are still associated with attributable mortality rates of up to 11.5% and may extend ICU stay by up to 12 days ([@bibr22-1757177416657162]; [@bibr25-1757177416657162]). Each CRBSI has been estimated to cost \$16,550 and initiatives to reduce this complication raise the possibility of substantial savings ([@bibr18-1757177416657162]).

More recently, improvements in quality of care have focused on initiatives with a care bundle of evidence-based interventions. For example, the introduction of a central venous insertion bundle into multiple ICUs in Michigan, which included implementation and close monitoring of hand hygiene, the application of chlorhexidine skin preparations and the use of the subclavian vein resulted in a decrease of CR-BSI by 66% ([@bibr21-1757177416657162]).

Many interventions are included in the current guidelines for insertion and care of CVCs. The guidelines available include those from the UK's National Institute for Health and Care Excellence (NICE) relating to infections in primary care ([@bibr16-1757177416657162]), epic3 which present national guidelines primarily for hospitals in UK ([@bibr12-1757177416657162]) and the Healthcare Infection Control Practices Advisory Committee (HICPAC) guidelines in US ([@bibr18-1757177416657162]). The interventions recommended include: full barrier precautions during insertion; use of a 2% chlorhexidine gluconate in alcohol for care of the catheter insertion site; the application of sterile transparent dressings to cover the insertion site with replacement at least every 7 days; and the use of alcohol to disinfect hubs and ports prior to access.

Additional approaches to prevent CRBSI have included the introduction of new technological innovations, including antiseptic impregnated central catheters and chlorhexidine impregnated sponge dressings, which have also been associated with significant reductions in infection rates ([@bibr2-1757177416657162]; [@bibr29-1757177416657162]). In certain healthcare institutions, where both bundle interventions and technological solutions have been implemented, the prospect of zero CRBSI is considered to be a potential goal. ([@bibr33-1757177416657162]).

More recently, the epic3 updated guideline included the recommendation to use a 2% chlorhexidine gel dressing for intravascular catheters ([@bibr13-1757177416657162]). The purpose of the current study was to develop a model to evaluate the economic value of implementing such a 2% chlorhexidine gel dressing in the care of insertion sites associated with CVC and arterial catheters in critically ill adult patients. There is a paucity of studies which have demonstrated cost-savings with individual infection prevention interventions. In the UK, NICE ([@bibr15-1757177416657162]) uses cost-consequence analysis to evaluate medical devices. We therefore used a similar approach to estimate the cost impact of introducing Tegaderm chlorhexidine gluconate (CHG) dressing (3M Health Care, Loughborough, UK) into clinical practice in adult critical care. The Tegaderm CHG dressing delivers chlorhexidine over 7 days from an integrated gel pad placed over the point of insertion of an intravascular catheter. A previous study ([@bibr28-1757177416657162]) has suggested it is associated with significant reductions in CRBSI compared to standard, non-medicated, transparent film dressings (standard intravenous \[i.v.\] dressings). This paper describes a decision analytic model, informed by parameters derived from published data, which has been used to estimate costs associated with the use of Tegaderm CHG i.v. dressings compared with standard i.v. dressings.

Material and methods {#section6-1757177416657162}
====================

A decision analytical model ([@bibr20-1757177416657162]) was developed using Microsoft Excel software (Microsoft Corporation) to estimate the economic impact of a Tegaderm CHG dressing when compared with standard i.v. dressings (defined as standard non-antimicrobial transparent film dressings) for patients admitted to an ICU requiring an intravascular catheter. The economic perspective of the model is the National Health Service (NHS) in England and Wales. The model used a short time horizon and the structure of the model is shown in [Figure 1](#fig1-1757177416657162){ref-type="fig"}.

![Model structure.](10.1177_1757177416657162-fig1){#fig1-1757177416657162}

The model assigned each patient with an indwelling intravascular catheter and a standard i.v. dressing, a baseline risk of associated dermatitis, local infection at the catheter insertion site and CRBSI. The risks of these events for patients with a Tegaderm CHG were estimated by applying the effectiveness parameters derived from the published literature to the baseline risks. Costs were accrued through costs of intervention (i.e. Tegaderm CHG or standard i.v. dressing) and hospital treatment costs depended on whether the patients had dermatitis, local infection or CRBSI. Results were estimated as mean values of 10,000 probabilistic sensitivity analysis (PSA) runs, each run with a different estimate for the risks, hazard ratios (HR) and costs sampled from probability distributions representing uncertainty in the parameter estimates.

Baseline risks {#section7-1757177416657162}
--------------

Baseline risks were estimated using data from existing medical literature. The outcomes included in the model were: (1) CRBSI; (2) local site infection; and (3) dermatitis.

The baseline primary outcome measure, CRBSI, was estimated from 'Matching Michigan': a 2-year study of central venous CRBSI in ICUs in England ([@bibr1-1757177416657162]). This study reported an average rate of 1.48 catheter-related infections per 1000 adult catheter days, which is similar to the rate reported in other studies ([@bibr7-1757177416657162]; [@bibr28-1757177416657162]). The average length of stay in an ICU for a patient with a catheter has been estimated to be 10 days, a value that has been used in another economic analysis ([@bibr32-1757177416657162]). In the economic model, CRBSI risk per patient was estimated by multiplying this length of stay by the CRBSI rate which resulted in a mean CRBSI risk of 0.0148 per patient.

A key secondary outcome measure of interest was the local site infection rate. There are substantially different estimates of incidence reported in various sources, with incidence in the range of 10--30%. [@bibr4-1757177416657162] used a local infection rate of 18.1% in their economic analysis and [@bibr31-1757177416657162] reported a rate of local site infection of 30%. However, [@bibr19-1757177416657162] reported the rate of local site infection as 10% when using non-antimicrobial transparent film dressings. This figure was also used in the economic analysis by [@bibr32-1757177416657162] concerning an antimicrobial patch. In this current economic model, a conservative estimate of a mean local site infection rate of 10% was used as shown in [Table 1](#table1-1757177416657162){ref-type="table"} for the base case analysis.

###### 

Summary of model parameters.

![](10.1177_1757177416657162-table1)

  ----------------------------------------------------------------------------------------------------------------------------------
  Parameter                                  Mean                       Distribution                  Source
  ------------------------------------------ -------------------------- ----------------------------- ------------------------------
  Average length of catheterisation          10 days                    Normal (10, 2)                [@bibr28-1757177416657162]

  *Baseline risks*                                                                                    

  CRBSI risk (per 1000 catheter days)\       1.48/1000 catheter days\   Normal (1.48, 0.075)\         [@bibr1-1757177416657162]\
  Local site infection risk (per patient)\   0.1\                       Normal (0.1, 1)\              [@bibr32-1757177416657162]\
  Dermatitis risk (per catheter)             0.0026                     Normal (0.0026, 0.0002)       [@bibr24-1757177416657162],\
                                                                                                      [@bibr28-1757177416657162]

  *HRs for Tegaderm CHG*                                                                              

  CRBSI\                                     0.402\                     Lognormal (--0.911, 0.393)\   [@bibr28-1757177416657162]\
  Local site infection\                      0.402\                     Lognormal (--0.911, 0.393)\   [@bibr28-1757177416657162]\
  Dermatitis (as RR)                         4.4                        Lognormal (1.482, --0.489)    [@bibr28-1757177416657162]

  *Costs (in £)*                                                                                      

  Unit cost of standard i.v. dressings\      £1.34\                     Fixed\                        3M\
  Unit cost of Tegaderm CHG dressings\       £6.21\                     Fixed\                        3M\
  CRBSI\                                     £9900\                     Gamma (198, 50)\              [@bibr10-1757177416657162]\
  Local site infection\                      £250\                      Gamma (50, 5)\                [@bibr23-1757177416657162]\
  Dermatitis                                 £150                       Gamma (30, 5)                 [@bibr24-1757177416657162]
  ----------------------------------------------------------------------------------------------------------------------------------

Normal distribution is represented with mean and SD, with 95% of the values in the distribution lying between 2 SDs on either side of the mean, e.g. normal (10, 2) implies that 95% of the samples lie between 6 and 14. Lognormal distribution is a continuous probability distribution whose logarithm is normally distributed. Gamma (a, b) distribution, where *a* is the shape parameter and *b* is the scale parameter, is typically used for skewed distributions and has a mean expected value of a × b, e.g. the average value of the samples of distribution Gamma (198, 50) is 9900 (i.e. 198 × 50).

Another outcome of interest was dermatitis. A dermatitis rate of 1.1% was associated with the use of Tegaderm CHG as compared to 0.29% for standard dressings ([@bibr28-1757177416657162]). However, this study was undertaken using a first generation version of the Tegaderm CHG dressing that appears to have a higher occurrence of this type of adverse event compared to the current version of the dressing that utilises a higher permeability film backing. Indeed, the introduction of a second generation Tegaderm CHG dressing was associated with a reduction in the number of skin reactions reported in Manufacturer and User Facility Device Experience from 2010 to 2012, and in numbers that were comparable to CHG sponge dressings ([@bibr11-1757177416657162]). In a study by [@bibr24-1757177416657162] on the clinical use of a CHG sponge dressing, a rate of device-related dermatitis of 1.1 and 4.1/1000 catheters for a 3 and 7 days CHG dressing change protocol, respectively, was reported. The rate of dermatitis in the current model was assumed to be the average of these two dressing change frequencies. In this current study, a mean dermatitis rate of 2.6/1000 catheters associated with the use of Tegaderm CHG dressing was therefore used as shown in [Table 1](#table1-1757177416657162){ref-type="table"}.

Effectiveness of Tegaderm CHG {#section8-1757177416657162}
-----------------------------

The effectiveness parameters for Tegaderm CHG dressing were estimated from [@bibr28-1757177416657162], the only relevant study identified in a systematic review which was undertaken in accordance with recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. The purpose of the review was to identify studies evaluating the effectiveness and safety of 3M Tegaderm CHG dressings compared to standard i.v. dressings used in routine care of patients (age \>18 years) admitted to a critical care setting such as an ICU who required intravascular access---via an arterial catheter or CVC or both---for at least 24 h. The details of the search strategy used are provided in the appendix.

HRs estimated from [@bibr28-1757177416657162] were used as effectiveness parameters in the model for Tegaderm CHG dressing. As used in [@bibr32-1757177416657162], the HR for local site infection was assumed to be the same as the HR for CRBSI. The probabilities of developing a CRBSI and local infections for patients given Tegaderm CHG dressing were estimated by applying the HRs to the baseline parameters. For dermatitis, the effectiveness of Tegaderm CHG dressing was modelled as a relative risk (RR) and the probability of dermatitis for patients with Tegaderm CHG dressing were estimated by applying the RR to the baseline dermatitis probability.

Costs {#section9-1757177416657162}
-----

The costs included in the model are the costs of the dressings and those associated with the treatment, where appropriate, for any local infections at the catheter insertion site, CRBSI and dermatitis. It was assumed that all other initial treatment costs were the same and were not included in the model. The Tegaderm CHG dressing is readily adopted into clinical practice and can directly replace standard i.v. dressing in the care pathways for arterial and CVCs. Therefore, no additional staff costs were included in the model.

The cost of standard care was estimated as the number of standard i.v. dressings required multiplied by the unit cost of this standard i.v. dressing. The number of dressings required was estimated by dividing the average duration of stay of a patient with a catheter on ICU in situ by the average dressing duration. The average length of stay for a patient with an intravascular catheter in situ on ICU was estimated to be 10 days ([@bibr32-1757177416657162]) and with the prescribed time for standard i.v. dressing being between 3 and 7 days, this resulted in three standard i.v. dressings required per patient. The unit cost of a standard i.v. dressing was £1.34, as shown in [Table 1](#table1-1757177416657162){ref-type="table"} and thus, in the model, the average cost of standard i.v. dressings per patient was calculated to be £4.02.

The cost of using Tegaderm CHG dressings per patient was estimated as the number of Tegaderm CHG dressings required multiplied by the unit cost of the Tegaderm CHG dressing. The unit cost of Tegaderm CHG dressing was £6.21 for the NHS as shown in [Table 1](#table1-1757177416657162){ref-type="table"}. Again, the number of dressings required was estimated by dividing the average length of stay of a patient on an ICU with a catheter by the average dressing duration. The average length of stay of a patient on an ICU with an indwelling intravascular catheter was taken as 10 days ([@bibr32-1757177416657162]) and an estimate of three dressings per patient resulted in the average cost of Tegaderm CHG dressings per patient being £18.63.

The main cost driver included in the model was the cost of CRBSI, which included costs of diagnosis, catheter replacement and the costs associated with increased length of stay. [@bibr24-1757177416657162] reported that the mean additional hospital length of stay for patients with CRBSI is 11 days, which resulted in a reported cost estimate of CRBSI in excess of \$25,000 ([@bibr24-1757177416657162]; [@bibr32-1757177416657162]). In Europe, additional length of stay in ICU has been reported as 9--10 days ([@bibr28-1757177416657162]). However, this was regarded as longer than that seen in many ICUs in the UK by our clinical experts (the co-authors of this manuscript), who considered that the average length of stay for a CRBSI patient will vary between 6 days (first 2 days in ICU and the remaining 4 days in a general medical ward) and 10 days (first 3 days in ICU and the remaining 7 days in a general medical ward). In a UK hospital, the cost of an average day in the ICU has been determined as being in the range of £1800--2400 with an additional £100 for the consultant time and consumables. This figure, in combination with the extra ward based costs of £480 per day, results in an average extra total cost of around £9750. Also, it is estimated that in clinical practice approximately 50% of intravascular catheters are removed due to suspected CRBSI and if they are subsequently replaced the cost is estimated to be £140 (acquisition cost of catheter £35; X-ray for confirming position of catheter £50 plus consumables of £15 plus staff costs to carry out the procedure at £40). In view of this, a figure of £140 for catheter replacement has been included in the total cost of CRBSI, which results in the overall CRBSI cost of £9890. This figure is very similar to that used in a Health Technology Assessment (HTA) ([@bibr10-1757177416657162]) who reported a mean CRBSI cost of £9148, that when inflated to present day costs using the hospital and community health services (HCHS) pay and price index ([@bibr5-1757177416657162]) is £9905. Thus, the cost of CRBSI used in the model is £9900 as shown in [Table 1](#table1-1757177416657162){ref-type="table"}.

The cost of treatment for a local site infection was reported as \$400 ([@bibr23-1757177416657162]) and it was considered that a cost of £250 for treatment of local infection in UK was a reasonable estimate and was therefore adopted in the model as shown in [Table 1](#table1-1757177416657162){ref-type="table"}.

The costs of treating dermatitis were taken from [@bibr24-1757177416657162], who reported that contact dermatitis requires four standard i.v. dressings, removal of the catheter and insertion of a new catheter. They used a micro-costing approach to estimate the total costs as \$228. We considered that the equivalent cost of £150 for treatment of dermatitis was acceptable and this was used in the model as shown in [Table 1](#table1-1757177416657162){ref-type="table"}.

Summary of model parameters {#section10-1757177416657162}
---------------------------

The decision analytic model assigned a baseline risk of different events for each patient with standard i.v. dressing. The risks of these events for patients with Tegaderm CHG dressing were estimated by applying the HRs from published literature to the baseline risks. A summary of the model parameters is provided in [Table 1](#table1-1757177416657162){ref-type="table"}, along with their sources. The scope of this study was adult intensive care patients.

Results {#section11-1757177416657162}
=======

First, we estimated the mean event rates that would be expected in a typical patient if Tegaderm CHG dressing were implemented instead of standard care. Tegaderm CHG dressing reduces the all event rates per patient except for dermatitis ([Table 2](#table2-1757177416657162){ref-type="table"}). It is of note that the formulation of the Tegaderm CHG dressing was changed in 2011 to include a more permeable film on the back. The introduction of second generation Tegaderm CHG dressing was associated with a reduction in the number of skin reactions reported in Manufacturer and User Facility Device from 2010 to 2012 ([@bibr8-1757177416657162]).

###### 

Summary of clinical risks associated with either the standard i.v. dressing or Tegaderm CHG.

![](10.1177_1757177416657162-table2)

  Clinical risk                             Standard i.v. dressing        Tegaderm CHG
  ----------------------------------------- ----------------------------- ----------------------------
  CRBSI risk                                1.48 per 1000 catheter days   0.6 per 1000 catheter days
  Local site infection risk (per patient)   10%                           4.25%
  Dermatitis risk (per patient)             0.26%                         1.11%

We then estimated the costs that would be expected in a typical service for 1000 adult patients who require a short-term intravascular catheter located in an ICU where Tegaderm CHG dressing was the routine dressing instead of a standard i.v. dressing. Results were estimated as mean values of 1000 probabilistic sensitivity analysis runs, each run with a different estimate for the risks, HRs and costs sampled from the probability distributions reported in [Table 1](#table1-1757177416657162){ref-type="table"}. The model showed use of Tegaderm CHG dressing results in an overall saving of £77,427 per 1000 patients, i.e. an average cost saving of £77 (95% CI, £76.70--78.10) per adult patient. The Tegaderm CHG dressing therefore has a 98.5% probability of being cost-saving compared to standard i.v. dressings.

The total cost-savings is provided as a breakdown of the individual cost differences as shown in [Table 3](#table3-1757177416657162){ref-type="table"}. Most of the savings described are due to a reduction in suspected and confirmed CRBSI. There are higher costs associated with the acquisition of CHG dressings but the savings in reduced event rates more than offset these costs associated with the technology, as seen in [Figure 2](#fig2-1757177416657162){ref-type="fig"}.

###### 

Breakdown of cost results.

![](10.1177_1757177416657162-table3)

                         Standard i.v. Dressing   Tegaderm CHG   Difference
  ---------------------- ------------------------ -------------- ------------
  Dressing costs         £4021                    £18,631        £14,610
  CRBSI                  £146,457                 £63,603        −£82,854
  Local site infection   £24,997                  £11,153        −£13,844
  Dermatitis             £1166                    £5826          £4660
  Total costs            £176,639                 £99,212        −£77,427

![Breakdown of the different costs for standard and Tegaderm CHG dressings (for a cohort of 10,000 patients).](10.1177_1757177416657162-fig2){#fig2-1757177416657162}

One-way sensitivity analysis was performed on all the model parameters. The baseline CRBSI risks and unit cost of CRBSI were identified as the key cost drivers while the rest of the parameters did not have an impact on the results or conclusions. Thus, only the results of sensitivity analysis for CRBSI risks and costs are presented here. At a lower CRBSI baseline risk of 0.5 per 1000 catheter days, the mean cost savings were £22,747 and at a higher estimate of 2.5 per 1000 catheter days, the mean cost savings were £133,591. At a lower cost estimate of CRBSI of £5000, the mean cost savings were £36,174 while the cost savings were £119,040 at a higher estimate of £15,000. Thus the lower the CRBSI baseline risk and cost of CRBSI, the lower the cost savings. Similarly, the higher the baseline risk of CRBSI and the cost of CRBSI, the higher the average cost savings. Threshold analysis conducted suggested that the baseline CRBSI risk has to be lower than 0.1 per 1000 catheter days for Tegaderm CHG dressing to not be cost-saving.

Discussion {#section12-1757177416657162}
==========

Our analyses suggest that Tegaderm CHG dressing is a cost-saving strategy when implemented for care of adult patients with intravascular catheters in ICU. Tegaderm CHG dressing results in an overall savings of £77,427 per 1000 adult patients, i.e. an average cost saving of £77 per patient compared to standard care with a 98.5% probability of being cost-saving compared to standard i.v. dressings. A 12-bed ICU is estimated to admit approximately 770 patients each year, the majority of whom will receive an intravascular catheter. The estimated cost savings for replacement of standard i.v. dressings with Tegaderm CHG dressing in such a unit is £59,600 per annum. The results were robust to sensitivity analyses performed on the baseline CRBSI risks and unit cost of CRBSI. These average cost-savings reported are for units that follow the English national trend for incidence of CRBSI reported by [@bibr1-1757177416657162]. Interestingly, the model also indicates that cost-savings can be found even in units with levels of CRBSI as low as 0.33 per 1000 catheter days.

Dermatitis has been identified as an adverse event that has a higher risk for CHG containing dressings compared to standard i.v. dressings. The results from this study indicate that the costs associated with the management of the related dermatitis per patient has a mean of £4.66. Another, albeit uncommon but potentially serious, adverse event associated with the use of chlorhexidine containing products is anaphylaxis ([@bibr14-1757177416657162]). However, no systemic adverse events associated with use of Tegaderm CHG dressing were reported during a comparative study including 1879 adult patients ([@bibr28-1757177416657162]) and the potential costs associated with anaphylaxis were not included in the model. It is of note that Tegaderm CHG dressing is not indicated for use in patients aged under 2 months and our study only included adult patients.

There are other published analyses studies of CHG impregnated devices including CHG dressings, but to date none of them included Tegaderm CHG gel dressing. The analysis reported by [@bibr30-1757177416657162] compared the number of CRBSIs associated with CHG impregnated and standard intravascular catheters and suggested that antiseptic impregnated catheters are cost-saving. [@bibr4-1757177416657162] performed a trial based evaluation and concluded that CHG sponge dressings would reduce costs, local infections and CRBSIs, and associated mortality. Similarly, [@bibr10-1757177416657162] developed a decision analytic model for patients requiring CVCs in the UK and suggested that antimicrobial CVCs are cost-saving. More recently, [@bibr32-1757177416657162] suggested that a CHG dressing is also a cost-effective CRBSI prevention treatment option. Furthermore, [@bibr24-1757177416657162] performed a trial based evaluation comparing both 3- and 7-day CHG dressing with standard dressings and concluded that CHG dressings are associated with financial savings. Our findings for Tegaderm CHG dressing are, therefore, in line with those reported in previous studies for antimicrobial devices used to prevent catheter-related infections.

The analysis reported in this paper has some limitations. Any modelling process involves simplifications and assumptions that may not accurately reflect local clinical practice. Owing to the lack of detail of cost estimates in research studies included in the analysis, scenarios were developed and their costs were independently reviewed by members of the research team. The uncertainties about the assumptions made in the estimation of these costs (especially CRBSI costs) were tested using scenario analysis and the conclusion that Tegaderm CHG dressing is cost-saving remains valid in these analyses. Threshold analysis performed suggested that the findings are robust and that large fluctuations in the CRBSI rates and cost parameters are needed before Tegaderm CHG dressing becomes cost incurring.

The results of the current analysis have important implications for the healthcare systems facing rising demand from emergency admissions into ICUs. The evidence suggests that the use of Tegaderm CHG dressing may substantially reduce the incidence of CRBSI and in doing so reduce the length of stay on an adult ICU and in subsequent clinical areas. This would also reduce the need for the use of antibiotic therapy and the risk of emergence of antimicrobial resistant microorganisms. The introduction of Tegaderm CHG dressings may also alleviate some pressure on acute beds and have associated consequent cost-savings. In concurrence with these findings, NICE has recently issued guidance suggesting that Tegaderm CHG dressing is cost-saving for the NHS in England and Wales ([@bibr17-1757177416657162]).
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